Autres langues AstraZeneca PLC NYSE

Actions

AZN

US0463531089

Produits pharmaceutiques

Marché Fermé - NYSE Autres places de cotation 22:00:02 20/07/2026			Après clôture 02:00:00
164,52 ^USD	-2,59%		148,55	-9,71%

08:08	Pas de vacances pour la géopolitique
07:10	Novartis dépasse les prévisions avec un bénéfice de 6 milliards de dollars malgré l'expiration de ses brevets	RE

Autres langues

07:10	Novartis beats forecasts with $6 billion profit as it navigates expiring patents
20/07	European Stocks Close Mixed in Monday Trading; Energy Stocks Rise Amid Expanding Middle East Fighting
20/07	AstraZeneca Unit Highlights Opportunities in Rare Diseases
20/07	Novartis faces drug pipeline test with valuation premium in focus
20/07	Could AI chip boom make ASML Europe's first trillion-dollar firm?
17/07	WOCHENVORSCHAU/27. Juli bis 1. August (31. KW)
16/07	Illumina, Inc., Formation Bio, Astrazeneca, Merck, and Eli Lilly and Company Expand Billion Cell Atlas Alliance with New Ai Drug Developers
16/07	Molecular Partners Doses First Patients in Phase 2 Study of Biliary Tract Cancer Therapy
16/07	Keymed Biosciences Expects Return to Profit in H1
15/07	Dizal Announces Global Exclusive License Agreement with AstraZeneca for Zegfrovy
15/07	Innovent Biologics Shares Surge on Spero Deal That Could Be Worth $1.1 Billion
14/07	US FDA approves Celcuity's breast cancer drug
14/07	AstraZeneca PLC agreed to acquire worldwide rights to develop and commercialise Zegfrovy from Dizal Pharmaceutical Co., Ltd. for $1.5 billion.
14/07	UK Shares Rise as Investors Weigh Middle East Tensions; BP Gains
14/07	Where would AI lead Pharma in the long run?
14/07	Global markets live: JPMorgan, BoA, Paramount, IBM, TSMC…
14/07	Europese beurzen lager door oplopende olieprijs
14/07	AstraZeneca Licenses Zegfrovy From Dizal in Up to $1.5 Billion Deal
14/07	European Midday Briefing : Shares Fall, Oil Hits One-Month High on Middle East Tensions
14/07	AstraZeneca Enters Exclusive Global License Agreement Fornovel Oral EGFR Inhibitor Zegfrovy for Lung Cancer with Dizal Pharmaceutical
14/07	AstraZeneca buys worldwide rights to cancer drug for USD1.5 billion
14/07	Dizal Pharmaceutical Co., Ltd. Grants Astrazeneca plc Worldwide Rights to Develop and Commercialise Zegfrovy
14/07	UK Stocks-Factors to watch on July 14
14/07	BP production falls; Astra lands USD1.5 billion deal
14/07	Astrazeneca schließt exklusiven Lizenzvertrag für Lungenkrebsmittel Zegfrovy